Oxaliplatin, a third-generation, platinum-based agent is widely used, most commonly in the FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) regimen, which is the first-line therapy in metastatic colorectal adenocarcinoma and adjuvant chemotherapy in stage III colorectal cancer. Platinum-based products are well known for causing hypersensitivity reactions. Fever associated with oxaliplatin-hypersensitivity reactions typically follows a specific pattern. It usually starts during the oxaliplatin infusion or immediately after (within hours instead of days) and happens after several administrations (mean 2–25) with unpredictable clinical presentations. We report a case of oxaliplatin-induced hypersensitivity reaction manifesting as fever but with unusual presentation than the aforementioned features.
RothenbergMLOzaAMBigelowRH. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol2003; 21: 2059–2069.
4.
LorgisVChauffertBGentilJ. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. Anticancer Res2012; 32: 4125–4130.
5.
MuggiaFM. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. Semin Oncol2004; 31: 17–24.
ShaoYYHuFCLiangJT. Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. J Formos Med Assoc2010; 109: 362–368.
8.
SiuSWChanRTAuGK. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol2006; 17: 259–261.
9.
MoriYNishimuraTKitanoT. Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Oncology2010; 79: 136–143.
10.
KimBHBradleyTTaiJ. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology2009; 76: 231–238.
11.
LeeKHParkYJKimES. Hypersensitivity reactions to oxaliplatin. Cancer Res Treat2006; 38: 240–241.
12.
IchikawaYGotoAHirokawaS. Allergic reactions to oxaliplatin in a single institute in Japan. Jpn J Clin Oncol2009; 39: 616–620.
13.
SekiKSenzakiKTsudukiY. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci2011; 8: 210–215.
14.
ParelMRanchonFNosbaumA. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol2014; 15: 1–1.
15.
AndreTBoniCMounedji-BoudiafL. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med2004; 350: 2343–2351.
16.
LeeCGianosMKlaustermeyerWB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol2009; 102: 179–187. quiz 187-179, 222.17.
17.
SyrigouESyrigosKSaifMW. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep2008; 8: 56–62.
18.
PaganiM. The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am2010; 94: 835–852, xiii.
19.
SaifMRoySLedbetterL. Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer oxaliplatin-induced hypersensitivity reaction. World J Gastroenterol2007; 13: 5277–5281.
20.
ThomasRRQuinnMGSchulerB. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer2003; 97: 2301–2307.
21.
Ulrich-PurHPenzMFiebigerWC. Oxaliplatin-induced fever and release of IL-6. Oncology2000; 59: 187–189.
22.
MeyerLZuberbierTWormM. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol2002; 20: 1146–1147.
23.
BhargavaPGammonDMcCormickMJ. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer2004; 100: 211–212.
24.
SaifMW. Hypersensitivity reactions associated with oxaliplatin. Expert Opin Drug Saf2006; 5: 687–694.
BrandiGPantaleoMAGalliC. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer2003; 89: 477–481.
27.
BasuRRajkumarADattaNR. Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int J Clin Oncol2002; 7: 365–367.
28.
RobinsonJBSinghDBodurka-BeversDC. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol2001; 82: 550–558.
29.
KorenCYerushalmiRKatzA. Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol2002; 25: 625–626.
30.
Confino-CohenRFishmanAAltarasM. Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer2005; 104: 640–643.
31.
KeatKHarnettPFulcherDA. Carboplatin desensitization. Ann Allergy Asthma Immunol2007; 99: 468–469.
Madrigal-BurgaletaRBerges-GimenoMPAngel-PereiraD. Desensitizing oxaliplatin-induced fever: a case report. J Investig Allergol Clin Immunol2013; 23: 435–436.
34.
GastaminzaGde la BorbollaJMGoikoetxeaMJ. A new rapid desensitization protocol for chemotherapy agents. J Investig Allergol Clin Immunol2011; 21: 108–112.
Gell PGH, Coombs RRA and Lachmann PJ. Clinical aspects of immunology, 3rd ed. Oxford Philadelphia: Blackwell Scientific Publications, 1975.
37.
ShibataYAriyamaHBabaE. Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol2009; 14: 397–401.
38.
SuenagaMMizunumaNShinozakiE. Management of allergic reactions to oxaliplatin in colorectal cancer patients. J Support Oncol2008; 6: 373–378.
39.
PolyzosATsavarisNGogasH. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology2009; 76: 36–41.
40.
StahlMKosterWWilkeH. Reaction after oxaliplatin–prevention with corticosteroids?Ann Oncol2001; 12: 874–874.
41.
SantiniDToniniGSalernoA. Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol2001; 12: 132–133.
42.
ToniniGSantiniDVincenziB. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. J Biol Regul Homeost Agents2002; 16: 105–109.
43.
Maindrault-GoebelFAndreTTournigandC. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer2005; 41: 2262–2267.
44.
LanctotKLNaranjoCA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Ther1995; 58: 692–698.
45.
LeeSYKangHRSongWJ. Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure. Cancer Chemother Pharmacol2014; 73: 1021–1029.
46.
MisLFernandoNHHurwitzHI. Successful desensitization to oxaliplatin. Ann Pharmacother2005; 39: 966–969.
47.
LimKHHuangMJLinHC. Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. Anticancer Drugs2004; 15: 605–607.
